Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BNT165c

Vaccine (mRNA vaccine) · Immune activation · developed by BioNTech

Phase 1/2 Most advanced trial (none active)
BNTX Developer
1 Registered trials

What is BNT165c?

BNT165c is a multi-antigen RNA-based vaccine administered by intramuscular injection for active immunization against malaria. It is being studied in malaria, including falciparum malaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (mRNA vaccine)
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06069544 Phase 1/2 Malaria Completed BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malaria

More from BioNTech

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind BNT165c

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.